KDM1A and triple-negative breast carcinoma: Among these emerging agents, combined LSD1(lysine-specific histone demethylase 1) and HDAC inhibition has shown promise in pre-clinical models of triple-negative breast cancer, reducing proliferative capacity while simultaneously decreasing senescence-associated inflammation.